2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD47

CD47

Cluster of Differentiation 47; MER6; OA3

CD47 is a glycoprotein that was first identified in 1990 as a protein that associates with integrins, hence its original name integrin-associated protein. CD47 interacts with SIRPα (CD172a or SHPS-1) and its family member SIRPγ, CD47 also interacts with integrins and secreted glycoprotein extracellular matrix protein thrombospondin-1 (TSP-1). Signaling through the CD47/SIRPα axis plays a role in various homeostatic processes, such as maintenance of erythrocytes, innate immune cells and T cells. Moreover, cancer cells and virus-infected and bacteria-infected cells can upregulate CD47 protein expression to prevent immune-mediated elimination.

CD47 Related Products (46):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P990694
    Zeripatamig
    		Inhibitor 99.85%
    Zeripatamig is an anti-CD19/CD47 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Zeripatamig
  • HY-P990555
    BI-765063
    		Inhibitor
    BI-765063 is a humanized antibody expressed in CHO that targets SIRPa/CD172a. BI-765063 contains an IgG4PE type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.36 kDa. The isotype control for BI-765063 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
    BI-765063
  • HY-P99950
    Evorpacept
    		Inhibitor 99.75%
    Evorpacept is a high affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region.
    Evorpacept
  • HY-115983
    DMUP
    		Inhibitor ≥98.0%
    DMUP is a potent CD47-SIRPα axis inhibitor. DMUP induces apoptosis and increases the macrophage phagocytosis in A549 cells. DMUP decreases the expression of CD47 and SIRPα protein. DMUP shows antitumor activity.
    DMUP
  • HY-P990707
    Maplirpacept
    Maplirpacept (TTI-622; PF-07901801) is a fusion protein consisting of the CD47-binding domain of human SIRPα linked to the Fc region of human IgG4. Maplirpacept enhances phagocytosis by blocking CD47.
    Maplirpacept
  • HY-151132
    Glutaminyl cyclases-IN-1
    		Inhibitor 98.21%
    Glutaminyl cyclases-IN-1 (IsoQC-IN-1) is a potent glutaminyl cyclases (QC) inhibitor with IC50 values of 12 nM and 73 nM for human QC and isoQC, respectively. Glutaminyl cyclases-IN-1 can selectively interfere with the interaction of CD47/SIRPα through isoQC inhibition, and enhances the increased phagocytic activity of both THP-1 and U937 macrophages.
    Glutaminyl cyclases-IN-1
  • HY-143224
    NCGC00138783
    		Inhibitor
    NCGC00138783 is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 µM. NCGC00138783 directly blocks the interaction between CD47 and SIRPα axis.
    NCGC00138783
  • HY-P991027
    Spevatamig
    HY-P991027 is an CD47/CLDN18-targeting (H-γ1_L-κ)_(H-γ1_L-κ) type bispecific antibody.
    Spevatamig
  • HY-P990723
    Timdarpacept
    		Inhibitor 99.95%
    Timdarpacept (DNL310) is a recombinant SIRPa-Fc fusion protein that can activate macrophages to enhance anti-tumor activity by blocking CD47-SIRPa.
    Timdarpacept
  • HY-P991023
    Safimestomig
    HY-P991023 is an CD47/CD274-targeting IgG4κ type bispecific antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Safimestomig
  • HY-P991062
    Gentulizumab
    		Inhibitor
    Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets CD47. Gentulizumab displays strong binding to CD47 in both human and monkey, and effectively inhibits the CD47-SIRPα interaction. Gentulizumab exhibits a potent antitumor activity. The isotype control for Gentulizumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Gentulizumab
  • HY-P990899
    Amostomig
    HY-P990899 is an CD274/CD47-targeting IgG1λ2 type humanized antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096).
    Amostomig
  • HY-P991004
    Itanistomig
    HY-P991004 is an CD274/CD47-targeting (VH-G1CH1-h)-H-γ1_L-κ-L-κ type bispecific antibody.
    Itanistomig
  • HY-P990954
    Amulirafusp alfa
    HY-P990954 is an MS4A1/CD47-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
    Amulirafusp alfa
  • HY-P991016
    Peluntamig
    HY-P991016 is an CD47/DLL3-targeting H-γ1_L-κ type bispecific antibody.
    Peluntamig
  • HY-P3968
    Thrombospondin-1 (1016-1021) (human, bovine, mouse)
    Thrombospondin-1 (1016-1021) (human, bovine, mouse), a Thrombospondin-1-derived peptide, is a truncated peptide devoid of CD47-binding activity.
    Thrombospondin-1 (1016-1021) (human, bovine, mouse)
  • HY-P991518
    IBI-322
    		Inhibitor
    IBI-322 is a bispecific antibody targeting PD-L1 and CD47. IBI-322 attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. IBI-322 selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro.
    IBI-322
  • HY-P10813
    ZLIRTLHEWY
    		Inhibitor
    ZLIRTLHEWY is a potent peptide CD47/SIRPα interaction inhibitor. ZLIRTLHEWY is promising for research of cancers.
    ZLIRTLHEWY
  • HY-143224A
    NCGC00138783 free base
    		Inhibitor
    NCGC00138783 free base is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 µM. NCGC00138783 free base directly blocks the interaction between CD47 and SIRPα axis.
    NCGC00138783 free base
  • HY-143225
    NCGC00538431
    		Inhibitor
    NCGC00538431 is a potent modulator of SIRPα-CD47.
    NCGC00538431